Lonafarnib

Chemical formula: C₂₇H₃₁Br₂ClN₄O₂  Molecular mass: 638.822 g/mol  PubChem compound: 148195

Therapeutic indications

Lonafarnib is indicated for:

Hutchinson-Gilford progeria syndrome

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Lonafarnib is indicated for the treatment of patients 12 months of age and older with a genetically confirmed diagnosis of Hutchinson-Gilford progeria syndrome or a processing-deficient progeroid laminopathy associated with either a heterozygous LMNA mutation with progerin-like protein accumulation or a homozygous or compound heterozygous ZMPSTE24 mutation.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Lonafarnib is contraindicated in the following cases:

Strong CYP3A inhibitors

at least one of
Strong CYP3A4 inhibitors
Cytochrome P-450 CYP3A5 strong inhibitors

Severe hepatic impairment

Hepatic failure stage IV

Medicinal products that are predominantly metabolised by CYP3A4

CYP3A4 substrates

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2022: ZOKINVY Hard capsule
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈